-69%

est. 2Y upside i

HealthcareSeries A

Rank

#2817

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Medium

The equity opportunity is tied to Fullscript, which acquired Rupa Health in October 2024.

Last updated: March 10, 2026

Bull (25%)+100%

Rupa Health's lab platform becomes the industry standard for functional medicine, growing its revenue to $150M+ within two years and significantly expanding Fullscript's market reach, contributing to Fullscript reaching a $5B+ valuation.

Base (55%)+20%

Rupa Health successfully integrates, growing its revenue to $50M within two years, solidifying Fullscript's "whole person care" offering and supporting Fullscript's steady growth to a $3B valuation.

Bear (20%)-30%

Rupa Health faces intense competition from established lab providers and integration challenges, limiting its growth to $20M-$30M and failing to significantly impact Fullscript's valuation, which could decline to $1.75B due to broader market pressures.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Fullscript has raised approximately $267M in funding on a $2.5B valuation, meaning investors hold roughly $267M in liquidation preferences.

Dilution Risk

moderate

While Fullscript is profitable, future capital raises for growth or acquisitions could dilute existing equity holders.

Secondary Liquidity

limited

Fullscript has seen secondary deals for existing investors, indicating some avenues for liquidity, but a formal active secondary market for employees is not confirmed.

Other — 2 roles

View all 2 open roles at Rupa Health →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Rupa Health's data — designed to show you've done your homework.

  • 1

    “Given Rupa Health's integration into Fullscript, how is the team thinking about leveraging Fullscript's existing practitioner network to accelerate Rupa's market penetration in specialty lab testing?”

  • 2

    “What are the key performance indicators for the Rupa Health division within Fullscript, and how will its success be measured over the next 12-24 months?”

  • 3

    “Considering Fullscript's $2.5B valuation and recent secondary deals, what is the company's long-term strategy for employee liquidity, and how does the Rupa Health team contribute to that vision?”

Community

Valuation Sentiment

Our model estimates -69% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.